You can lose up to 24kg!

Eli Lilly and Company announced today that tirzepatide, an investigational dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, is being used in the treatment of obesity.

The company's GIP/GLP-1 receptor dual agonist, tirzepatide, can activate both GLP-1 receptor and GIP receptor-mediated signaling pathways, and may reduce body weight through a variety of mechanisms, including reducing appetite and increasing energy expenditure , as well as improving the function of beta cells that secrete insulin,

▲ Potential mechanism of action of Tirzepatide (Image source: Eli Lilly's official website)

In this randomized, double-blind, placebo-controlled Phase 3 trial called SURMOUNT-1, people with obesity (without type 2 diabetes), or those with hypertension, dyslipidemia, obstructive sleep apnea or The overweight population with at least one comorbidity of cardiovascular disease received either placebo or tirzepatide (in doses of 5 mg, 10 mg, or 15 mg)

Trial results showed that tirzepatide met the co-primary endpoint of the trial, with a mean weight loss of 16.

▲Tirzepatide significantly reduces the weight of obese individuals (Image source: Eli Lilly's official website)

In addition, 89% (5 mg group) and 96% (10 mg and 15 mg group) of the groups receiving tirzepatide achieved at least a 5% weight loss, respectively, compared with 28% in the control group

▲Tirzepatide allows more obese individuals to achieve weight loss of more than 5% or 20% (Image source: Eli Lilly’s official website)

In terms of safety and tolerability, the profile of tirzepatide is similar to other incretin-based weight loss therapies

"Tirzepatide is the first investigational drug to reduce average body weight by more than 20% in a Phase 3 clinical trial, and these results reinforce our confidence in its potential to help people with obesity,

Eli Lilly is currently testing tirzepatide in various other phase 3 clinical trials in different types of obesity, with results expected next year

▲The clinical development plan of Tirzepatide (Image source: Eli Lilly's official website)

Historically, most diet pills can only reduce body weight by 5-10%, and there are many safety hazards

Related reading: Safely lose 15% of your body weight! What is the next breakthrough direction for weight loss therapy?

References:

[1] Lilly's tirzepatide delivered up to 22.